Literature DB >> 11606482

Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation.

F Massiéra1, M Bloch-Faure, D Ceiler, K Murakami, A Fukamizu, J M Gasc, A Quignard-Boulange, R Negrel, G Ailhaud, J Seydoux, P Meneton, M Teboul.   

Abstract

White adipose tissue and liver are important angiotensinogen (AGT) production sites. Until now, plasma AGT was considered to be a reflection of hepatic production. Because plasma AGT concentration has been reported to correlate with blood pressure, and to be associated with body mass index, we investigated whether adipose AGT is released locally and into the blood stream. For this purpose, we have generated transgenic mice either in which adipose AGT is overexpressed or in which AGT expression is restricted to adipose tissue. This was achieved by the use of the aP2 adipocyte-specific promoter driving the expression of rat agt cDNA in both wild-type and hypotensive AGT-deficient mice. Our results show that in both genotypes, targeted expression of AGT in adipose tissue increases fat mass. Mice whose AGT expression is restricted to adipose tissue have AGT circulating in the blood stream, are normotensive, and exhibit restored renal function compared with AGT-deficient mice. Moreover, mice that overexpress adipose AGT have increased levels of circulating AGT, compared with wild-type mice, and are hypertensive. These animal models demonstrate that AGT produced by adipose tissue plays a role in both local adipose tissue development and in the endocrine system, which supports a role of adipose AGT in hypertensive obese patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606482     DOI: 10.1096/fj.01-0457fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  137 in total

Review 1.  Control of body weight: a physiologic and transgenic perspective.

Authors:  G Frühbeck; J Gómez-Ambrosi
Journal:  Diabetologia       Date:  2003-02-15       Impact factor: 10.122

2.  Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice.

Authors:  Frederique Yiannikouris; Michael Karounos; Richard Charnigo; Victoria L English; Debra L Rateri; Alan Daugherty; Lisa A Cassis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-11-09       Impact factor: 3.619

Review 3.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

4.  Polymorphism in miR-31 and miR-584 binding site in the angiotensinogen gene differentially influences body fat distribution in both sexes.

Authors:  Jan Machal; Jan Novak; Renata Hezova; Filip Zlamal; Anna Vasku; Ondrej Slaby; Julie Bienertova-Vasku
Journal:  Genes Nutr       Date:  2015-08-26       Impact factor: 5.523

Review 5.  Type 2 diabetes mellitus and hypertension: an update.

Authors:  Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 6.  Inhibition of angiogenesis: a new function for angiotensinogen and des(angiotensin I)angiotensinogen.

Authors:  Pierre Corvol; Noel Lamandé; Amauri Cruz; Jerome Celerier; Jean-Marie Gasc
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 7.  Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.

Authors:  Jonathan G Owen; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

Review 8.  Neuroimmune communication in hypertension and obesity: a new therapeutic angle?

Authors:  Annette D de Kloet; Eric G Krause; Peng D Shi; Jasenka Zubcevic; Mohan K Raizada; Colin Sumners
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

9.  Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

Authors:  Yau-Sheng Tsai; Hyo-Jeong Kim; Nobuyuki Takahashi; Hyung-Suk Kim; John R Hagaman; Jason K Kim; Nobuyo Maeda
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values.

Authors:  Aldo S Villecco; Cinzia Cocci; Maurizio Di Emidio
Journal:  Curr Ther Res Clin Exp       Date:  2004-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.